Prostate Cancer Early Detection, Version 1.2023 Featured Updates to the NCCN Guidelines

The NCCN Guidelines for Prostate Cancer Early Detection provide recommendations for individuals with a prostate who opt to participate in an early detection program after receiving the appropriate counseling on the pros and cons. These NCCN Guidelines Insights provide a sum-mary of recent updates to the NCCN Guidelines with regard to the testing protocol, use of multiparametric MRI

[1]  J. Lillard,et al.  Racial disparities in Black men with prostate cancer: A literature review , 2022, Cancer.

[2]  S. Narod,et al.  The Effect of Age on Prostate Cancer Survival , 2022, Cancers.

[3]  R. V. D. van den Bergh,et al.  Prostate Cancer Detection Percentages of Repeat Biopsy in Patients with Positive Multiparametric Magnetic Resonance Imaging (Prostate Imaging Reporting and Data System/Likert 3-5) and Negative Initial Biopsy. A Mini Systematic Review. , 2022, European urology.

[4]  A. Vickers,et al.  A Nationwide Analysis of Risk of Prostate Cancer Diagnosis and Mortality following an Initial Negative Transrectal Ultrasound Biopsy with Long-Term Followup , 2022, The Journal of urology.

[5]  J. Morote,et al.  The current recommendation for the management of isolated high‐grade prostatic intraepithelial neoplasia , 2021, BJU international.

[6]  Ruth Etzioni,et al.  The Impact of Intensifying Prostate Cancer Screening in Black Men: A Model-Based Analysis. , 2021, Journal of the National Cancer Institute.

[7]  C. Earle,et al.  Comparison of Multiparametric Magnetic Resonance Imaging-Targeted Biopsy With Systematic Transrectal Ultrasonography Biopsy for Biopsy-Naive Men at Risk for Prostate Cancer: A Phase 3 Randomized Clinical Trial. , 2021, JAMA oncology.

[8]  Jane M Lange,et al.  Lifetime Benefits and Harms of Prostate-Specific Antigen–Based Risk-Stratified Screening for Prostate Cancer , 2020, JNCI Journal of the National Cancer Institute.

[9]  F. Hamdy,et al.  Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in the Detection of Clinically Significant Prostate Cancer in the Prostate Imaging Reporting and Data System Era: A Systematic Review and Meta-analysis. , 2020, European urology.

[10]  Baris Turkbey,et al.  Variability of the Positive Predictive Value of PI-RADS for Prostate MRI across 26 Centers: Experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel. , 2020, Radiology.

[11]  P. Stattin,et al.  Prespecified Four Kallikrein Marker Model (4Kscore) at Age 50 or 60 for Early Detection of Lethal Prostate Cancer in a Large Population-Based Cohort of Asymptomatic Men Followed for 20 Years. , 2020, The Journal of urology.

[12]  E. Lengerich,et al.  Temporal and spatial trends and determinants of aggressive prostate cancer among Black and White men with prostate cancer , 2019, Cancer Causes & Control.

[13]  O. Rouvière,et al.  The primacy of multiparametric MRI in men with suspected prostate cancer , 2019, European Radiology.

[14]  A. Kibel,et al.  Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men. , 2019, European urology.

[15]  B. Mahal,et al.  Prostate Cancer–Specific Mortality Across Gleason Scores in Black vs Nonblack Men , 2018, JAMA.

[16]  B. Hadaschik,et al.  Multicentre evaluation of magnetic resonance imaging supported transperineal prostate biopsy in biopsy‐naïve men with suspicion of prostate cancer , 2018, BJU international.

[17]  S. Spaner,et al.  The role of mpMRI and PSA density in patients with an initial negative prostatic biopsy , 2018, World Journal of Urology.

[18]  D. Margolis,et al.  MRI‐Targeted or Standard Biopsy for Prostate‐Cancer Diagnosis , 2018, The New England journal of medicine.

[19]  L. Holmberg,et al.  Age at diagnosis and prostate cancer treatment and prognosis: a population-based cohort study , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  Richard E. Fan,et al.  Prostate Magnetic Resonance Imaging Interpretation Varies Substantially Across Radiologists. , 2017, European urology focus.

[21]  D. Moses,et al.  A multiparametric magnetic resonance imaging‐based risk model to determine the risk of significant prostate cancer prior to biopsy , 2017, BJU international.

[22]  Jonathan E. Shoag,et al.  Use of Digital Rectal Examination as an Adjunct to Prostate Specific Antigen in the Detection of Clinically Significant Prostate Cancer , 2017, The Journal of urology.

[23]  P. Humphrey,et al.  Negative Multiparametric Magnetic Resonance Imaging of the Prostate Predicts Absence of Clinically Significant Prostate Cancer on 12-Core Template Prostate Biopsy. , 2017, Urology.

[24]  H. D. de Koning,et al.  Is prostate cancer different in black men? Answers from 3 natural history models , 2017, Cancer.

[25]  S. Eggener,et al.  Prostate cancer detection following diagnosis of atypical small acinar proliferation. , 2017, The Canadian journal of urology.

[26]  Yipeng Hu,et al.  The PICTURE study: diagnostic accuracy of multiparametric MRI in men requiring a repeat prostate biopsy , 2017, British Journal of Cancer.

[27]  H. Thomsen,et al.  Clinical Outcome Following Low Suspicion Multiparametric Prostate Magnetic Resonance Imaging or Benign Magnetic Resonance Imaging Guided Biopsy to Detect Prostate Cancer , 2017, The Journal of urology.

[28]  Jason D. Wright,et al.  Prognostic Significance of Digital Rectal Examination and Prostate Specific Antigen in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Arm , 2017, The Journal of urology.

[29]  A. Kibel,et al.  Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  I. Staff,et al.  Incidence of Clinically Significant Prostate Cancer After a Diagnosis of Atypical Small Acinar Proliferation, High-grade Prostatic Intraepithelial Neoplasia, or Benign Tissue. , 2016, Urology.

[31]  Adam T Froemming,et al.  Interobserver Reproducibility of the PI-RADS Version 2 Lexicon: A Multicenter Study of Six Experienced Prostate Radiologists. , 2016, Radiology.

[32]  Ronald C. Chen,et al.  Stage at presentation and survival outcomes of patients with Gleason 8-10 prostate cancer and low prostate-specific antigen. , 2016, Urologic oncology.

[33]  D. Golijanin,et al.  Atypical Small Acinar Proliferation: Repeat Biopsy and Detection of High Grade Prostate Cancer , 2015, Prostate cancer.

[34]  R. Dorin,et al.  Prostate atypia: Does repeat biopsy detect clinically significant prostate cancer? , 2015, The Prostate.

[35]  A. Vickers,et al.  Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study , 2014, BMJ : British Medical Journal.

[36]  P. Scardino,et al.  Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study , 2013, BMJ : British Medical Journal.

[37]  S. Taneja,et al.  Prostate cancer diagnosis among men with isolated high-grade intraepithelial neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral toremifene. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  J. Gohagan,et al.  Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. , 2012, Journal of the National Cancer Institute.

[39]  D. Bostwick,et al.  Precursors of prostate cancer , 2012, Histopathology.

[40]  E. Messing,et al.  Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality , 2011 .

[41]  M. Cooperberg,et al.  Impact of age at diagnosis on prostate cancer treatment and survival. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  P. Scardino,et al.  Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study , 2010, BMJ : British Medical Journal.

[43]  B. G. Blijenberg,et al.  Screening and prostate-cancer mortality in a randomized European study. , 2009, The New England journal of medicine.

[44]  J. Moul,et al.  Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras. , 2009, The Journal of urology.

[45]  M. Roobol,et al.  The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam. , 2008, European urology.

[46]  M. Roobol,et al.  Screening for prostate cancer at low PSA range: The impact of digital rectal examination on tumor incidence and tumor characteristics , 2007, The Prostate.

[47]  W. Catalona,et al.  Characteristics of prostate cancer detected by digital rectal examination only. , 2006, Urology.

[48]  M. Roobol,et al.  Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam). , 2005, Urology.

[49]  Fritz H. Schröder,et al.  Evaluation of the Digital Rectal Examination as a Screening Test for Prostate Cancer , 1998 .

[50]  Louis R Kavoussi,et al.  Accuracy of digital rectal examination and transrectal ultrasonography in localizing prostate cancer. , 1994, The Journal of urology.

[51]  J. Richie,et al.  COMPARISON OF DIGITAL RECTAL EXAMINATION AND SERUM PROSTATE SPECIFIC ANTIGEN IN THE EARLY DETECTION OF PROSTATE CANCER: RESULTS OF A MULTICENTER CLINICAL TRIAL OF 6,630 MEN , 1994, The Journal of urology.

[52]  W. Catalona,et al.  Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. , 1993, JAMA.

[53]  Laurent Lemaitre,et al.  Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. , 2019, The Lancet. Oncology.

[54]  Baris Turkbey,et al.  What Are We Missing? False-Negative Cancers at Multiparametric MR Imaging of the Prostate. , 2018, Radiology.

[55]  E. Orihuela,et al.  Atypical small acinar proliferation at index prostate biopsy: rethinking the re-biopsy paradigm , 2017, International Urology and Nephrology.

[56]  B. Mahal,et al.  Association of very low prostate‐specific antigen levels with increased cancer‐specific death in men with high‐grade prostate cancer , 2016, Cancer.

[57]  P. Scardino,et al.  Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: A case-control study , 2008, BMC medicine.

[58]  R. Dhir.  Prostate Specific Antigen Testing Among the Elderly–When To Stop? , 2010 .

[59]  Igor Sartori,et al.  Detection of Organ-Confined Prostate Cancer Is Increased Through Prostate- Specific Antigen-Based Screening: , 1994 .